Monopar Q1 net loss $1.6M; pivots to radiopharma pipeline, winding down other programs

Monopar Therapeutics

Net loss $1.6M ($0.10/shr) vs $2.4M ($0.19/shr) in Q1 2023.
Cash and short-term investments $8.8M as of Mar 31, 2024, sufficient through June 2025.
Company winding down non-radiopharma programs (camsirubicin, MNPR-202) to focus on MNPR-101 radiopharma.
First-in-human Phase 1 trial of MNPR-101-Zr initiated; targeting MNPR-101-RIT Phase 1 launch by Q4 2024/Q1 2025.
Additional funding will be needed within the next 12 months to support operations beyond current runway.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Monopar Therapeutics reported first quarter ended March 31, 2024 results: net income $1.6 million, EPS $0.10 per share.

Period: first quarter ended March 31, 2024
Net income: $1.6 million
EPS: $0.10 per share
Result: reported results

Exact text from the filing

Net loss for the first quarter of 2024 was $1.6 million or $0.10 per share compared to net loss of $2.4 million or $0.19 per share for the first quarter of 2023.

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

Monopar Therapeutics filing history →

Source: SEC EDGAR

accession 0001437749-24-015453

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.